Safety of pegylated interferon and ribavirin therapy for chronic hepatitis C in patients with sickle cell anemia

Table 1 Clinical data of SCA patients with chronic hepatitis

Total No. of patients	52
Sex	30 F: 22 M
Mean age (range)	29.5 (15-54) years
Mean HbS (range)	74.4% (66%-89%)
Mean HbF (range)	22.5% (9.6%-33.6%)
G6PD deficiency	12 (23.1%)
Mean HCV-RNA viral load (range)	986330 IU/mL (range 12762-3329282 IU/mL)
HCV genotype
genotype 1	13 (8 non-responders)
genotype 2	20 (2 non-responders)
genotype 3	6
genotype 4	8 (4 non-responders)
genotype 5	1 (1 non-responder)
not available	4
Mean Hb level
At start of treatment	10.2 g/dL (7.5-11.5 g/dL)
At 3 mo of treatment	10.4 g/dL (8.9-11.2 g/dL)
At 6 mo of treatment	10.35 g/dL (8.5-11.9 g/dL)
At the end of treatment	10.3 g/dL (8.2-11.7 g/dL)
SVR at 6 mo after the end of treatment	37 (71.2%)

SCA: Sickle cell anemia; SVR: Sustained viral response; HCV: Chronic hepatitis C.